Why Is Hims Stock Crashing, and is it a Buying Opportunity?
Summary
Parkev explains that Hims & Hers recently reported quarterly results that disappointed investors, leading to a nearly 19% drop in share price. While revenue grew by 49% and subscribers by 13%, Parkev points out that the real highlight was the 30% increase in monthly revenue per subscriber to $105, indicating strong loyalty from existing customers. Parkev notes that the company's direct-to-consumer model is well-positioned to disrupt the complex and often frustrating U.S. healthcare system by removing intermediaries.
However, Parkev highlights significant concerns regarding rising expenses. General and administrative costs nearly doubled to $151.5 million, which Parkev suggests might be linked to a recent acquisition. This surge in spending caused operating income to swing from an $11.8 million profit to a $66 million loss. Additionally, Parkev mentions that operating cash flow dropped significantly from $239 million to $119 million year-over-year, leaving less capital for activities like share buybacks.
Regarding valuation and specific stock outlook:
Mentioned Stocks
Reasoning: Parkev identifies strong top-line growth of 49% and a significant 30% increase in revenue per user as key indicators of customer value. Despite a massive spike in administrative expenses and a drop in cash flow, Parkev provides a fair value estimate of $22 per share. With the current price around $19, Parkev argues the stock is undervalued, though Parkev now holds this buy recommendation with a lower level of conviction than before.